Commerce Dashboard

Biocon Ltd

Go Back

Biocon Ltd

  • Total consolidated income of Rs. 73,603 million (US$ 1.00 billion) in FY21.
  • Started a clinical trial in India to study Itolizumab in treating moderate to severe patients with COVID-19 complications.
  • Is the sixth-largest manufacturer of sodium bicarbonate worldwide.
  • Expanded commercial footprint of key biosimilar, including Pegfilgrastim (Australia, Canada), Trastuzumab (the US, Australia, Canada) and Insulin Glargine (Australia) through its partner Mylan.

Biocon is Asia's premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, lifesaving biotherapeutics by making them affordable for patients across the world. Biocon is among the few companies globally to have received approvals for its biosimilars from developed countries like the U.S., EU, Australia, and Japan. It’s credibility as a serious player in the biosimilars sector was first established with the Japanese approval for Insulin Glargine. The credibility was enhanced when Biocon, along with partner Mylan, became the first global company to get biosimilar Trastuzumab and Pegfilgrastim approved in the US in 2017 and 2018, respectively. It was also among the first few to receive Insulin Glargine approval in Europe and Australia for Insulin Glargine, both in partnership with Mylan. It also established its presence in key emerging markets through safe, effective, and high quality biosimilars including recombinant human insulin.

Company Website:



In February 2021, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., partnered with The International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF’s Core Mission initiative and activities

In January 2021, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., received Rs. 555-crore (US$ 75 Million) capital injection from a primary equity investment firm ADQ

In November 2020, Biocon Biologics received US$ 150 million capital injection from Goldman Sachs

On July 13, 2020, Biocon got approval from Drugs Controller General of India (DCGI) to launch biologic drug Itolizumab for treatment of moderate to severe COVID-19 patients

With the subsidiary of China Medical System Holdings Ltd. (CMS), Biocon signed the license and supply agreement for three generic formulation products in Greater China

Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia
2018 Sandoz Biosimilars collaboration signed
2018 The U.S. FDA approves Fulphila™, co-developed by Biocon and Mylan and Therapeutic Goods Administration, Australia approves biosimilar Insulin Glargine, Semglee™ 100 IU/mL 3 mL prefilled pen
2017 Launched Ogrivi™, first biosimilar of trastuzumab approved by US FDA
2016 Insulin Glargine pen for people with diabetes launched in Japan as the first biosimilar from India
2014 Biocon introduced CANMAb™ - Trastuzumab for Treating Breast Cancer in India
2011 Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device
2006 India’s first indigenously produced novel monoclonal antibody, Nimotuzumab, for head & neck cancer launched
2002 Clinigene's clinical laboratory is the first in India to receive CAP accreditation
2000 Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals and establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development
1997 Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility
1993 Biocon scales up its in-house research programme
1979 Biocon is the first Indian company to manufacture and export enzymes to USA and Europe
Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw


Science and R&D
At rank 48, India stands among the top 50 countries in the Global Innovation Index 2020.